<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="pmcid: 7319607S0306-9877(20)31200-7 doi: 10.1016/j.mehy.2020.110027110027 : Article Why the lower reported" exact="prevalence" post="of asthma in patients diagnosed with COVID-19 validates repurposing"/>
 <result pre="of EDTA excipients in nebulized Î²2-agonist medicines can disrupt SARS-CoV-2/COVID-19" exact="infection" post="and can explain the asthma paradox. This model validates"/>
 <result pre="at an initial target dose of 2.4Â mg per aerosol" exact="treatment" post="is readily achievable with standard nebulizer and mechanical ventilator"/>
 <result pre="mechanical ventilator equipment. EDTA warrants further investigation as a potential" exact="treatment" post="for SARS-CoV-2/COVID-19 in consideration of the new calcium requirements"/>
 <result pre="SARS-CoV-2/COVID-19 in consideration of the new calcium requirements for virus" exact="infection" post="and the regular presence of EDTA excipients in common"/>
 <result pre="[4]. HCoV-229E is highly prevalent and most people experience acute" exact="infection" post="during their childhood [5]. One study found 65% of"/>
 <result pre="as substrate recognition sites. Calcium-dependent fusion process required for viral" exact="infection" post="Even now, the actual mechanism ofÂ virus membrane fusionÂ"/>
 <result pre="recently discovered for Rubella [16] and later described for SARS-CoV-1" exact="infection" post="[17]. While two fusion peptides (FLs) were found with"/>
 <result pre="CoVs and the apparent resistance of asthma patients to SARS-CoV-2" exact="infection" post="due to inhaling medications containing EDTA excipients. Strategy for"/>
 <result pre="a novel anti-coronavirus drugs for SARS-CoV-2/COVID-19. The strategies for Coronavirus" exact="treatment" post="regimens have mainly relied on combination therapies with drugs"/>
 <result pre="deleterious effects were observed when corticosteroids (methylprednisolone) were given as" exact="treatment" post="during the SARS and MERS epidemics [19], [20]. Additionally,"/>
 <result pre="indicates that corticosteroids should not be given routinely for the" exact="treatment" post="of COVID-19. Accordingly, the asthma paradox is unlikely due"/>
 <result pre="treatments becauseÂ recent admonitions against routine systematic corticosteroids for the" exact="treatment" post="of COVID-19 and prior reports indicate that systemic steroids"/>
 <result pre="Recent medical articles indicate that there isÂ markedly lower reported" exact="prevalence" post="of asthma and COPD in patients diagnosed with COVID-19"/>
 <result pre="the SARS-CoV-2 (COVID-19) spike protein (i.e., the ligand), 3)SARS-CoV-2 (COVID-19)" exact="infection" post="is, and has been disrupted by exposure to calcium"/>
 <result pre="the study is directed towards utilizing objective parameters that distinguish" exact="treatment" post="groups. Parameters could include, RT-PCR results, clincal progress, and/or"/>
 <result pre="be used to directly demonstrate that EDTA can inhibit SARS-CoV-2" exact="infection" post="with relative safety based on prior studies of asthmatics"/>
 <result pre="nebulizer set-up should mitigate most EDTA induced bronchoconstriction. As a" exact="treatment" post="example, assuming the volume from a standard dropper is"/>
 <result pre="to achieve a target dose of 2.4Â mg per aerosol" exact="treatment" post="with or without a Beta2-agonist as tolerated. HCoV-229E was"/>
 <result pre="mechanisms to elucidate why asthma patients appear resistant to COVID-19" exact="infection" post="uncovered evidence for the key role of calcium in"/>
 <result pre="with or without Beta-2 agonist supplementation logically becomes a new" exact="treatment" post="for COVID-19/SARS-CoV-2 patients. The potential to utilize EDTA to"/>
 <result pre="to utilize EDTA to both reduce COVID-19 transmission and treat" exact="infection" post="through relatively safe modalities that include nebulizer or mechanical"/>
 <result pre="range up of to 1Â·2 to 12Â·8 mg/mL for the" exact="treatment" post="of COVID-19 patients on respirators or with stand-alone nebulizers."/>
 <result pre="antiviral drug discoveryExpert Opin Drug Discov144201939741230849247 19StockmanL.J.BellamyR.GarnerP.SARS: systematic review of" exact="treatment" post="effectsPLoS Med392006e343 20MorraM.E.Van ThanhL.KamelM.G.Clinical outcomes of current medical approaches"/>
 <result pre="and meta-analysisRev Med Virol2832018e1977 21RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet39510223202047347532043983 22AsmusM.J.ShermanJ.HendelesL.Bronchoconstrictor additives in bronchodilator solutionsJ"/>
 <result pre="Badia JR, Agusti A. Do chronic respiratory diseases or their" exact="treatment" post="affect the risk of SARS-CoV-2 infection? Lancet Respir Med.Â"/>
 <result pre="39CallowK.A.ParryH.F.SergeantM.TyrrellD.A.J.The time course of the immune response to experimental coronavirus" exact="infection" post="of manEpidemiol Infect1052199043544610.1017/S09502688000480192170159 40U.S. Considering COVID-19 Immunity Cards: What"/>
</results>
